Community pharmacist intervention in depressed primary care patients (PRODEFAR study): randomized controlled trial protocol

Rubio-Valera, Maria; Serrano-Blanco, Antoni; Travé, Pere; Teresa Peñarrubia-María, M.; Ruiz, Mar; Pujol, Marian March
January 2009
BMC Public Health;2009, Vol. 9 Issue 1, p284
Academic Journal
Background: Treatment of depression, the most prevalent and costly mental disorder, needs to be improved. Non-concordance with clinical guidelines and non-adherence can limit the efficacy of pharmacological treatment of depression. Through pharmaceutical care, pharmacists can improve patients' compliance and wellbeing. The aim of this study is to evaluate the effectiveness and cost-effectiveness of a community pharmacist intervention developed to improve adherence and outcomes of primary care patients with depression. Methods/design: A randomized controlled trial, with 6-month follow-up, comparing patients receiving a pharmaceutical care support programme in primary care with patients receiving usual care. The total sample comprises 194 patients (aged between 18 and 75) diagnosed with depressive disorder in a primary care health centre in the province of Barcelona (Spain). Subjects will be asked for written informed consent in order to participate in the study. Diagnosis will be confirmed using the SCID-I. The intervention consists of an educational programme focused on improving knowledge about medication, making patients aware of the importance of compliance, reducing stigma, reassuring patients about side-effects and stressing the importance of carrying out general practitioners' advice. Measurements will take place at baseline, and after 3 and 6 months. Main outcome measure is compliance with antidepressants. Secondary outcomes include; clinical severity of depression (PHQ-9), anxiety (STAI-S), health-related quality of life (EuroQol-5D), satisfaction with the treatment received, side-effects, chronic physical conditions and sociodemographics. The use of healthcare and social care services will be assessed with an adapted version of the Client Service Receipt Inventory (CSRI). Discussion: This trial will provide valuable information for health professionals and policy makers on the effectiveness and cost-effectiveness of a pharmaceutical intervention programme in the context of primary care. Trial registration: NCT00794196


Related Articles

  • Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression. Bech, P.; Cialdella, P.; Haugh, M. C.; Birkett, M. A.; Hours, A.; Boissel, J. P.; Tollefson, G. D. // British Journal of Psychiatry;May2000, Vol. 176, p421 

    Background: Previous meta-analyses of fluoxetine as an antidepressant have many methodological problems, including diagnosis of major depression, validity of outcome measures and lack of intention-to-treat analyses.Aims: To provide an estimate of the effect of...

  • Randomized trial of pharmacist interventions to improve depression care and outcomes in primary care. Capoccia, Kam L.; Boudreau, Denise M.; Blough, David K.; Ellsworth, Allan J.; Clark, Dave R.; Stevens, Nancy G.; Katon, Wayne J.; Sullivan, Sean D. // American Journal of Health-System Pharmacy;2/15/2004, Vol. 61 Issue 4, p364 

    The impact of pharmacist interventions on the care and outcomes of patients with depression in a primary care setting was evaluated. Patients diagnosed with a new episode of depression and started on antidepressant medications were randomized to enhanced care (EC) or usual care (UC) for one...

  • The effect of forewarning on the occurrence of side-effects and discontinuance of medication in patients on amitriptyline. Myers, E. D.; Calvert, E. J. // British Journal of Psychiatry;Apr73, Vol. 122 Issue 569, p461 

    The article discusses the study on the impact of prevising patients taking amitriptyline on its side-effects. It is believed that psychological factors are significant in identifying the harmful or good effects of drugs. In an amitriptyline trial, patients were asked to note down their...

  • An Open Trial of Mirtazapine in Menopausal Women with Depression Unresponsive to Estrogen Replacement Therapy. Joffe, Hadine; Groninger, Heather; Soares, Claudio; Nonacs, Ruta; Cohen, Lee S. // Journal of Women's Health & Gender-Based Medicine;Dec2001, Vol. 10 Issue 10, p999 

    Treatment of major depression in menopausal women is controversial. Estrogen replacement therapy (ERT) treats mild depression but may not treat more severe depression in this population. Antidepressants are recommended as treatment for major depression in menopausal women, but the specific...

  • Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Katona, Cornelius L. E.; Abou-Saleh, Mohammed T.; Harrison, Deborah A.; Nairac, Bertrand A.; Edwards, Denzil R. L.; Lock, Toni; Burns, Robert A.; Robertson, Mary M.; Katona, C L; Abou-Saleh, M T; Harrison, D A; Nairac, B A; Edwards, D R; Lock, T; Burns, R A; Robertson, M M // British Journal of Psychiatry;Jan95, Vol. 166, p80 

    Background: This study was designed to establish whether (as suggested in a number of open and relatively small controlled trials) lithium augmentation is more effective than continued antidepressant alone, where response to a standard course of antidepressant treatment has been...

  • The Effect of Daily Self-Measurement of Pressure Pain Sensitivity Followed by Acupressure on Depression and Quality of Life versus Treatment as Usual in Ischemic Heart Disease: A Randomized Clinical Trial. Bergmann, Natasha; Ballegaard, Søren; Bech, Per; Hjalmarson, Åke; Krogh, Jesper; Gyntelberg, Finn; Faber, Jens // PLoS ONE;May2014, Vol. 9 Issue 5, p1 

    Background: Depressive symptoms and reduced quality of life (QOL) are parts of the chronic stress syndrome and predictive of adverse outcome in patients with ischemic heart disease (IHD). Chronic stress is associated with increased sensitivity for pain, which can be measured by algometry as...

  • Placebo—controlled trials in major depression are necessary and ethically justifiable. Adam, Dieter; Kasper, S.; Möller, H.-J.; Singer, E. A. // European Archives of Psychiatry & Clinical Neuroscience;2005, Vol. 255 Issue 4, p258 

    Despite numerous placebo–controlled clinical trials with antidepressants were conducted in humans and a large amount of data was already published in the last two decades, the members of the 4th European Expert Forum on Ethical Evaluation of Placebo–Controlled Studies in Depression...

  • Antidepressants and cardiovascular adverse events: A narrative review. Nezafati, Mohammad Hassan; Vojdanparast, Mohammad; Nezafati, Pouya // ARYA Atherosclerosis;Sep2015, Vol. 11 Issue 5, p295 

    BACKGROUND: Major depression or deterioration of previous mood disorders is a common adverse consequence of coronary heart disease, heart failure, and cardiac revascularization procedures. Therefore, treatment of depression is expected to result in improvement of mood condition in these...

  • A Natural Mood-Booster that Really Works.  // Natural Health;Jul2003, Vol. 33 Issue 5, p22 

    Antidepressants like Prozac and Elavil are not the only options for treating depression. According to a report by the U.S. Department of Health and Human Services, the supplement SAMe works as well as many prescription medications without side effects like stomach upset and decreased libido. A...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics